[CAPR] Capricor Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.53 Change: 0.13 (5.42%)
Ext. hours: Change: 0 (0%)

chart CAPR

Refresh chart

Strongest Trends Summary For CAPR

CAPR is in the long-term down -79% below S&P in 2 years and down -93% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS-0.86 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 71.59% Sales Growth - Q/Q27.53% P/E-0.81
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-30.88% ROE-115.81% ROI-50.49%
Current Ratio3.37 Quick Ratio Long Term Debt/Equity0.51 Debt Ratio1.03
Gross Margin Operating Margin-149.05% Net Profit Margin-153.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities16.48 M Cash From Investing Activities-15.52 M Cash From Operating Activities-2.05 M Gross Profit
Net Profit-3.48 M Operating Profit-3.41 M Total Assets27.47 M Total Current Assets25.42 M
Total Current Liabilities7.55 M Total Debt9.16 M Total Liabilities20.15 M Total Revenue1.79 M
Technical Data
High 52 week2.04 Low 52 week0.32 Last close0.44 Last change4.04%
RSI28.62 Average true range0.04 Beta0.24 Volume60.2 K
Simple moving average 20 days-5.49% Simple moving average 50 days-14.13% Simple moving average 200 days-55.21%
Performance Data
Performance Week1.64% Performance Month-20.55% Performance Quart-48.85% Performance Half-60.09%
Performance Year-75.97% Performance Year-to-date6.1% Volatility daily4.43% Volatility weekly9.9%
Volatility monthly20.3% Volatility yearly70.31% Relative Volume125.77% Average Volume306.88 K
New High New Low

News

2019-04-05 10:52:26 | Will Capricor Therapeutics, Inc.'s NASDAQ:CAPR Earnings Grow In The Years Ahead?

2019-03-28 16:25:39 | Capricor: 4Q Earnings Snapshot

2019-03-28 16:00:00 | Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

2019-03-21 08:00:00 | Capricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28

2019-02-21 07:40:02 | Capricor Therapeutics, Inc. NASDAQ:CAPR: Commentary On Fundamentals

2019-02-06 07:00:00 | Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy

2019-01-24 09:30:00 | 4 Healthcare Stocks Looking To Have A Strong Thursday 1/24/19

2019-01-24 07:00:00 | Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy

2019-01-22 07:00:00 | Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA

2019-01-18 14:56:57 | Does Capricor Therapeutics, Inc.’s NASDAQ:CAPR CEO Pay Reflect Performance?

2018-12-27 07:25:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth

2018-12-26 06:58:24 | U.S. drug developer Capricor places Duchenne drug trial on hold

2018-12-04 09:53:08 | Could The Capricor Therapeutics Inc NASDAQ:CAPR Ownership Structure Tell Us Something Useful?

2018-11-28 08:35:00 | Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-11-13 17:15:10 | Capricor Therapeutics CAPR Reports Q3 Loss, Lags Revenue Estimates

2018-11-13 16:09:29 | Capricor: 3Q Earnings Snapshot

2018-11-13 16:01:00 | Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

2018-11-12 07:00:00 | Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial

2018-11-08 07:00:00 | Capricor Therapeutics to Present Corporate Overview and Poster at Action Duchenne International Conference

2018-11-07 10:30:03 | Analysts Estimate Capricor Therapeutics CAPR to Report a Decline in Earnings: What to Look Out for

2018-11-06 07:00:00 | Capricor Therapeutics to Present Third Quarter Financial Results and Corporate Update on November 13

2018-11-02 07:00:00 | Capricor Therapeutics to Provide Corporate Update at BIO-Europe Conference on Nov. 6

2018-10-22 07:00:00 | Capricor Therapeutics to Participate in Upcoming Conferences  

2018-10-20 10:30:32 | Is Capricor Therapeutics Inc’s NASDAQ:CAPR 18% Better Than Average?

2018-10-17 09:00:00 | Market Trends Toward New Normal in Halozyme Therapeutics, Fitbit, Iconix Brand Group, Leap Therapeutics, LightPath Technologies, and Capricor Therapeutics — Emerging Consolidated Expectations, Analyst Ratings

2018-09-14 08:41:00 | S Spotlight On Capricor Therapeutics Inc’s NASDAQ:CAPR Fundamentals

2018-08-23 07:50:00 | New Research Coverage Highlights Live Nation Entertainment, LightPath Technologies, Synchronoss Technologies, Mallinckrodt public limited company, Capricor Therapeutics, and Mersana Therapeutics — Consolidated Revenues, Company Growth, and Expectations fo

2018-08-21 07:00:00 | Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles

2018-08-09 17:15:09 | Capricor Therapeutics CAPR Reports Q2 Loss, Misses Revenue Estimates

2018-08-09 16:12:29 | Capricor: 2Q Earnings Snapshot

2018-08-09 16:00:00 | Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

2018-08-02 16:00:00 | Capricor Therapeutics to Present Second Quarter Financial Results and Corporate Update on August 9

2018-07-17 08:56:01 | Benzinga Pro's 5 Stocks To Watch Today

2018-07-17 07:00:00 | Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops

2018-07-13 09:00:00 | Capricor Therapeutics and PPMD to Host Webinar for Duchenne Muscular Dystrophy Community on July 18

2018-06-28 07:00:00 | Capricor Therapeutics to Present at PPMD Annual Conference

2018-06-20 12:05:18 | Should You Be Holding Capricor Therapeutics Inc NASDAQ:CAPR?

2018-06-13 07:35:00 | Detailed Research: Economic Perspectives on CarGurus, ArcelorMittal, Capricor Therapeutics, B&G Foods, Ionis Pharmaceuticals, and Photronics — What Drives Growth in Today's Competitive Landscape

2018-06-01 16:34:23 | Does Capricor Therapeutics Inc’s NASDAQ:CAPR PE Ratio Warrant A Buy?

2018-05-29 07:00:00 | Capricor Therapeutics to Present at the 2018 BIO International Convention in Boston

2018-05-15 20:03:11 | How Did Capricor Therapeutics Inc’s NASDAQ:CAPR 23.03% ROE Fare Against The Industry?

2018-05-10 16:36:43 | Capricor: 1Q Earnings Snapshot

2018-05-10 16:00:00 | Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

2018-05-04 08:00:00 | Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10

2018-05-03 07:00:00 | Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal

2018-04-30 07:00:00 | Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy

2018-04-23 07:40:00 | Wired News – Capricor’s New Pre-Clinical Study Establishes that Repeated Doses of CAP-1002 Lead to Enhanced Exercise Capacity in a Disease Model of Duchenne Muscular Dystrophy

2018-04-19 07:00:00 | Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model

2018-04-12 07:00:00 | Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day

2018-04-06 10:00:00 | Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018